Abstract
Introduction: This study aimed to identify genetic predictors of treatment response and survival in patients with myeloid neoplasms treated with hypomethylating agents (HMAs). Methods: We performed next-generation sequencing on bone marrow aspiration samples of 59 patients diagnosed with acute myeloid leukemia (AML), myelodysplastic syndrome with excess blasts-2, or chronic myelomonocytic leukemia and treated with decitabine or azacitidine as a frontline therapy. Results: A single gene with the most common mutations was TP53 (14 of 59 patients), and mutations in RAS pathway-related genes including KRAS, NRAS, FLT3, PTPN11, CBL, and KIT were found in 28.8% of patients. The overall response rate to HMAs was 33.9%. Predictive factors for a poor response were an age >75 years (p = 0.007), 3 or more gene mutations (p = 0.004), mutations in RAS pathway-related genes (p = 0.033), and a mutated NRAS gene (p = 0.042). An age >75 years (hazard ratio 2.946), diagnosis of AML (hazard ratio 2.915), and mutations in NRAS (hazard ratio 4.440) were identified as poor prognostic factors for survival. Conclusion: In conclusion, mutations in RAS pathway-related genes were predictors of a poor response to HMAs. Particularly, mutated NRAS was associated with inferior survival rates.
References
1.
Diesch
J
, Zwick
A
, Garz
AK
, Palau
A
, Buschbeck
M
, Gotze
KS
. A clinical-molecular update on azanucleoside-based therapy for the treatment of hematologic cancers
. Clin Epigenetics
. 2016
;8
:71
. .2.
Fenaux
P
, Mufti
GJ
, Hellstrom-Lindberg
E
, Santini
V
, Finelli
C
, Giagounidis
A
, Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study
. Lancet Oncol
. 2009 Mar
;10
(3
):223
–32
. .3.
Lubbert
M
, Suciu
S
, Baila
L
, Ruter
BH
, Platzbecker
U
, Giagounidis
A
, Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group
. J Clin Oncol
. 2011 May 20
;29
(15
):1987
–96
. .4.
Kantarjian
HM
, Thomas
XG
, Dmoszynska
A
, Wierzbowska
A
, Mazur
G
, Mayer
J
, Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia
. J Clin Oncol
. 2012 Jul 20
;30
(21
):2670
–7
. .5.
Dombret
H
, Seymour
JF
, Butrym
A
, Wierzbowska
A
, Selleslag
D
, Jang
JH
, International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts
. Blood
. 2015 Jul 16
;126
(3
):291
–9
. .6.
Itzykson
R
, Kosmider
O
, Cluzeau
T
, Mansat-De Mas
V
, Dreyfus
F
, Beyne-Rauzy
O
, Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias
. Leukemia
. 2011 Jul
;25
(7
):1147
–52
. .7.
Bejar
R
, Lord
A
, Stevenson
K
, Bar-Natan
M
, Perez-Ladaga
A
, Zaneveld
J
, TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients
. Blood
. 2014 Oct 23
;124
(17
):2705
–12
. .8.
Traina
F
, Visconte
V
, Elson
P
, Tabarroki
A
, Jankowska
AM
, Hasrouni
E
, Impact of molecular mutations on treatment response to DNMT inhibitors in myelodysplasia and related neoplasms
. Leukemia
. 2014 Jan
;28
(1
):78
–87
. .9.
Coombs
CC
, Sallman
DA
, Devlin
SM
, Dixit
S
, Mohanty
A
, Knapp
K
, Mutational correlates of response to hypomethylating agent therapy in acute myeloid leukemia
. Haematologica
. 2016 Nov
;101
(11
):e457
–e60
. .10.
Welch
JS
, Petti
AA
, Miller
CA
, Fronick
CC
, O’Laughlin
M
, Fulton
RS
, TP53 and decitabine in acute myeloid leukemia and myelodysplastic syndromes
. N Engl J Med
. 2016 Nov 24
;375
(21
):2023
–36
. .11.
Chang
CK
, Zhao
YS
, Xu
F
, Guo
J
, Zhang
Z
, He
Q
, TP53 mutations predict decitabine-induced complete responses in patients with myelodysplastic syndromes
. Br J Haematol
. 2017 Feb
;176
(4
):600
–8
. .12.
Dohner
H
, Estey
E
, Grimwade
D
, Amadori
S
, Appelbaum
FR
, Buchner
T
, Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
. Blood
. 2017 Jan 26
;129
(4
):424
–47
. .13.
Garcia-Manero
G
. Myelodysplastic syndromes: 2012 update on diagnosis, risk-stratification, and management
. Am J Hematol
. 2012 Jul
;87
(7
):692
–701
. .14.
Cheson
BD
, Greenberg
PL
, Bennett
JM
, Lowenberg
B
, Wijermans
PW
, Nimer
SD
, Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia
. Blood
. 2006 Jul 15
;108
(2
):419
–25
. .15.
Patnaik
MM
, Barraco
D
, Lasho
TL
, Finke
CM
, Hanson
CA
, Ketterling
RP
, DNMT3A mutations are associated with inferior overall and leukemia-free survival in chronic myelomonocytic leukemia
. Am J Hematol
. 2017 Jan
;92
(1
):56
–61
. .16.
Bocchia
M
, Candoni
A
, Borlenghi
E
, Defina
M
, Fili
C
, Cattaneo
C
, Real-world experience with decitabine as a first-line treatment in 306 elderly acute myeloid leukaemia patients unfit for intensive chemotherapy
. Hematol Oncol
. 2019 Oct
;37
(4
):447
–55
. .17.
Lindsley
RC
, Mar
BG
, Mazzola
E
, Grauman
PV
, Shareef
S
, Allen
SL
, Acute myeloid leukemia ontogeny is defined by distinct somatic mutations
. Blood
. 2015 Feb 26
;125
(9
):1367
–76
. .18.
Lin
PH
, Li
HY
, Fan
SC
, Yuan
TH
, Chen
M
, Hsu
YH
, A targeted next-generation sequencing in the molecular risk stratification of adult acute myeloid leukemia: implications for clinical practice
. Cancer Med
. 2017 Feb
;6
(2
):349
–60
. .19.
Papaemmanuil
E
, Gerstung
M
, Bullinger
L
, Gaidzik
VI
, Paschka
P
, Roberts
ND
, Genomic classification and prognosis in acute myeloid leukemia
. N Engl J Med
. 2016 Jun 9
;374
(23
):2209
–21
. .20.
Hussaini
MO
, Mirza
AS
, Komrokji
R
, Lancet
J
, Padron
E
, Song
J
. Genetic landscape of acute myeloid leukemia interrogated by next-generation sequencing: a large cancer center experience
. Cancer Genomics Proteomics
. 2018 Mar-Apr
;15
(2
):121
–6
. .21.
Makishima
H
, Yoshizato
T
, Yoshida
K
, Sekeres
MA
, Radivoyevitch
T
, Suzuki
H
, Dynamics of clonal evolution in myelodysplastic syndromes
. Nat Genet
. 2017 Feb
;49
(2
):204
–12
. .22.
Lucas
N
, Duchmann
M
, Rameau
P
, Noel
F
, Michea
P
, Saada
V
, Biology and prognostic impact of clonal plasmacytoid dendritic cells in chronic myelomonocytic leukemia
. Leukemia
. 2019 Oct
;33
(10
):2466
–80
. .23.
Santos
FPS
, Getta
B
, Masarova
L
, Famulare
C
, Schulman
J
, Datoguia
TS
, Prognostic impact of RAS-pathway mutations in patients with myelofibrosis
. Leukemia
. 2020 Mar
;34
(3
):799
–810
. .24.
Bacher
U
, Haferlach
T
, Schoch
C
, Kern
W
, Schnittger
S
. Implications of NRAS mutations in AML: a study of 2502 patients
. Blood
. 2006 May 15
;107
(10
):3847
–53
. .25.
Yang
X
, Qian
J
, Sun
A
, Lin
J
, Xiao
G
, Yin
J
, RAS mutation analysis in a large cohort of Chinese patients with acute myeloid leukemia
. Clin Biochem
. 2013 May
;46
(7–8
):579
–83
. .26.
Prieto-Conde
MI
, Jimenez
C
, Garcia-Alvarez
M
, Ramos
F
, Medina
A
, Cuello
R
, Identification of relapse-associated gene mutations by next-generation sequencing in low-risk acute myeloid leukaemia patients
. Br J Haematol
. 2020 Mar 2
;189
(4
):718
–30
.27.
McMahon
CM
, Ferng
T
, Canaani
J
, Wang
ES
, Morrissette
JJD
, Eastburn
DJ
, Clonal selection with RAS pathway activation mediates secondary clinical resistance to selective FLT3 Inhibition in acute myeloid leukemia
. Cancer Discov
. 2019 Aug
;9
(8
):1050
–63
. .28.
DiNardo
CD
, Tiong
IS
, Quaglieri
A
, MacRaild
S
, Loghavi
S
, Brown
FC
, Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML
. Blood
. 2020 Mar 12
;135
(11
):791
–803
. .29.
Arber
DA
, Orazi
A
, Hasserjian
R
, Thiele
J
, Borowitz
MJ
, Le Beau
MM
, The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
. Blood
. 2016 May 19
;127
(20
):2391
–405
. .30.
Ricci
C
, Fermo
E
, Corti
S
, Molteni
M
, Faricciotti
A
, Cortelezzi
A
, RAS mutations contribute to evolution of chronic myelomonocytic leukemia to the proliferative variant
. Clin Cancer Res
. 2010 Apr 15
;16
(8
):2246
–56
. .31.
Bernard
E
, Nannya
Y
, Hasserjian
RP
, Devlin
SM
, Tuechler
H
, Medina-Martinez
JS
, Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes
. Nat Med
. 2020 Oct
;26
(10
):1549
–56
. .© 2021 S. Karger AG, Basel
2021
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
